MedTrace Logo

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2024-05-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.

Conditions

Interventions

BIOLOGICAL

Low dose ADP101

Active powder formulation

BIOLOGICAL

High dose ADP101

Active powder formulation.

BIOLOGICAL

Pooled Placebo

Placebo powder

Sponsors & Collaborators

  • Alladapt Immunotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mei-Lun Wang, MD · VP of Clinical Development, Alladapt Immunotherapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2022-11-22
Completion
2022-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04856865 on ClinicalTrials.gov